drugset / Trial / NCT02053350

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

NCT02053350

Phase 2 Terminated 7 enrolled University of Virginia
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the treatment of C. difficile infection. We hypothesize that alanyl-glutamine when given with standard antibiotic treatment for C. difficile infection will decrease diarrhea, mortality and recurrent disease.

Timeline

Start
2015-04
Primary completion
2017-04-05
Completion
2017-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alanyl-glutamine Peptide 4 g Oral
Subject Alanyl-glutamine Peptide 24 g Oral
Subject Alanyl-glutamine Peptide 44 g Oral